Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Paediatric Vaccine Market: By Type, By Technology, By Application and By Region Forecast 2019-2030
Paediatric Vaccine Market: By Type, By Technology, By Application and By Region Forecast 2019-2030
Paediatric Vaccine Market size was valued at US$ 40.7 billion in 2023 and grow at 10.3% CAGR from 2019 - 2023. Paediatric vaccinations are vital items used to prevent children from dangerous infections. They function by boosting the immune system to recognize and kill specific viruses or bacteria, resulting in a faster and more effective response if exposed to these pathogens in the future. These vaccinations endure accurate safety testing, including clinical trials, to ensure that they fulfil demanding quality criteria before being approved and distributed in countries around the world. Factors such as increased knowledge of vaccination advantages, economic growth, government assistance, and novel vaccine development initiatives by key companies are propelling the further. However, factors such as high vaccine costs, limited access in remote locations, and competition from lower cost biosimilars are impeding market growth.
Study Period
2024 - 2030Base Year
2023CAGR
10.3%Largest Market
North AmericaFastest Growing Market
Asia pacific
The paediatric vaccines market is characterized by various dynamic factors that drive growth. Increasing global awareness of the benefits of vaccination for preventing childhood illnesses is an important factor. Governments and healthcare organizations around the world promoting vaccination as an important public health precaution, which is helping to increase vaccine uptake. Technological improvements and innovations in vaccine development are critical for market growth. The introduction of new vaccinations that target a wider range of diseases, combined with advances in vaccine formulations and delivery systems, improves efficacy and safety profiles. For Example, Conjugate vaccines, which link polysaccharides to carrier proteins, have transformed vaccination by stimulating higher immune responses in both newborns and adults which resultant to drive the market.
Moreover, rising prevalence of paediatric infections, such as influenza and tetanus, as well as chronic problems like multiple sclerosis in teenagers, are further driving the market. Despite these factors, constraints such as high vaccine costs, particularly for novel formulations and combination vaccines, impede market expansion. Issues with vaccination supply chains, storage needs, and distribution logistics all have an impact on market dynamics. However, continuous research and development efforts, combined with strategic partnerships between pharmaceutical firms and healthcare providers, continue to drive innovation and overcome these difficulties, indicating a bright future for the market globally.
North American pediatric vaccination market is predicted to dominate the global market share due to owing to the well-established healthcare system, particularly in the United States, and an increase in immunization efforts. The planned child immunization programs run by the Centers for Disease Control and Prevention (CDC), high financing, widespread commercial availability of vaccines, and public awareness of vaccines all contribute to the US market's continued growth. Considering the variables that contribute to the enormous size of the United States pediatric vaccine industry, the country has the greatest percentage of children receiving immunizations. Furthermore, the CDC releases a recommended child and adolescent immunization schedule, including doses, every year for children in the United States. This significantly increases vaccination adoption among the pediatric population, contributing to market growth.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024 - 2030 |
|
Market Size in 2023 |
US$ 40.7 billion |
|
Market CAGR |
10.3% |
|
By Type |
|
|
By Technology |
|
|
By Application |
|
Download Free Sample Report
The paediatric vaccine market was valued at US$ 40.7 billion in 2023 and is projected to reach growing at a CAGR of 10.3 %.
The increasing incidence of several diseases in children, including pertussis, influenza, diphtheria, and tetanus, among other infectious and non-infectious diseases, is one of the primary drivers driving the growth of the pediatric vaccine market.
The increased use of novel vaccines has resulted in an increase in worldwide vaccination coverage, which has a further impact on the market.
Market research is segmented based on type, technology, application, and region.
North America is expected to have the largest market share and the greatest CAGR throughout the forecast period.
| 1. Executive Summary |
| 2. Global Paediatric Vaccine Market Introduction |
| 2.1.Global Paediatric Vaccine Market - Taxonomy |
| 2.2.Global Paediatric Vaccine Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Technology |
| 2.2.3.Application |
| 2.2.4.Region |
| 3. Global Paediatric Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Paediatric Vaccine Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Paediatric Vaccine Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Monovalent |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Multivalent |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global Paediatric Vaccine Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Live Attenuated Vaccines |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Inactivated Vaccines |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Toxoid Vaccines |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Subunit |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Recombinant |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Polysaccharide |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Conjugate Vaccines |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Others |
| 6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 7. Global Paediatric Vaccine Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Infectious Disease |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Diphtheria, Tetanus and Pertussis |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Allergy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Influenza |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Pneumococcal Disease |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Measles, Mumps, and Rubella |
| 7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Others |
| 7.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 8. Global Paediatric Vaccine Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Paediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Monovalent |
| 9.1.2.Multivalent |
| 9.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Live Attenuated Vaccines |
| 9.2.2.Inactivated Vaccines |
| 9.2.3.Toxoid Vaccines |
| 9.2.4.Subunit |
| 9.2.5.Recombinant |
| 9.2.6.Polysaccharide |
| 9.2.7.Conjugate Vaccines |
| 9.2.8.Others |
| 9.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Infectious Disease |
| 9.3.2.Diphtheria, Tetanus and Pertussis |
| 9.3.3.Allergy |
| 9.3.4.Influenza |
| 9.3.5.Pneumococcal Disease |
| 9.3.6.Measles, Mumps, and Rubella |
| 9.3.7.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Paediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Monovalent |
| 10.1.2.Multivalent |
| 10.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Live Attenuated Vaccines |
| 10.2.2.Inactivated Vaccines |
| 10.2.3.Toxoid Vaccines |
| 10.2.4.Subunit |
| 10.2.5.Recombinant |
| 10.2.6.Polysaccharide |
| 10.2.7.Conjugate Vaccines |
| 10.2.8.Others |
| 10.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Infectious Disease |
| 10.3.2.Diphtheria, Tetanus and Pertussis |
| 10.3.3.Allergy |
| 10.3.4.Influenza |
| 10.3.5.Pneumococcal Disease |
| 10.3.6.Measles, Mumps, and Rubella |
| 10.3.7.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Paediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Monovalent |
| 11.1.2.Multivalent |
| 11.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Live Attenuated Vaccines |
| 11.2.2.Inactivated Vaccines |
| 11.2.3.Toxoid Vaccines |
| 11.2.4.Subunit |
| 11.2.5.Recombinant |
| 11.2.6.Polysaccharide |
| 11.2.7.Conjugate Vaccines |
| 11.2.8.Others |
| 11.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Infectious Disease |
| 11.3.2.Diphtheria, Tetanus and Pertussis |
| 11.3.3.Allergy |
| 11.3.4.Influenza |
| 11.3.5.Pneumococcal Disease |
| 11.3.6.Measles, Mumps, and Rubella |
| 11.3.7.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Paediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Monovalent |
| 12.1.2.Multivalent |
| 12.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Live Attenuated Vaccines |
| 12.2.2.Inactivated Vaccines |
| 12.2.3.Toxoid Vaccines |
| 12.2.4.Subunit |
| 12.2.5.Recombinant |
| 12.2.6.Polysaccharide |
| 12.2.7.Conjugate Vaccines |
| 12.2.8.Others |
| 12.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Infectious Disease |
| 12.3.2.Diphtheria, Tetanus and Pertussis |
| 12.3.3.Allergy |
| 12.3.4.Influenza |
| 12.3.5.Pneumococcal Disease |
| 12.3.6.Measles, Mumps, and Rubella |
| 12.3.7.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Paediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Monovalent |
| 13.1.2.Multivalent |
| 13.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Live Attenuated Vaccines |
| 13.2.2.Inactivated Vaccines |
| 13.2.3.Toxoid Vaccines |
| 13.2.4.Subunit |
| 13.2.5.Recombinant |
| 13.2.6.Polysaccharide |
| 13.2.7.Conjugate Vaccines |
| 13.2.8.Others |
| 13.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Infectious Disease |
| 13.3.2.Diphtheria, Tetanus and Pertussis |
| 13.3.3.Allergy |
| 13.3.4.Influenza |
| 13.3.5.Pneumococcal Disease |
| 13.3.6.Measles, Mumps, and Rubella |
| 13.3.7.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Sinovac |
| 14.2.2.Sanofi |
| 14.2.3.Novartis AG |
| 14.2.4.Abbott |
| 14.2.5.AstraZeneca Plc |
| 14.2.6.Merck & Co Inc |
| 14.2.7.Emergent BioSolutions Inc |
| 14.2.8.Serum Institute of India Pvt. |
| 14.2.9.GSK |
| 14.2.10.Pfizer Inc |
| 14.2.11.CSL Limited |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.